Non-surgical interventions for the treatment of masticatory muscular spasticity in patients with cerebral palsy. Systematic review of randomized clinical trials

2021 ◽  
Author(s):  
Monise Mendes Rocha ◽  
Ana Luiza Cabrera Martimbianco ◽  
Rafael Zaratin Beltramin ◽  
Anna Carolina Ratto Tempestini Horliana ◽  
Elaine Marcílio Santos ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Cerebral Palsy ◽  
Randomized Clinical Trials ◽  
Surgical Interventions

scholarly journals Systematic review of reporting benefits and harms of surgical interventions in randomized clinical trials

BJS Open ◽  
2020 ◽  
Vol 4 (2) ◽  
pp. 171-181
Author(s):  
F. E. Stubenrouch ◽  
E. S. Cohen ◽  
P. M. M. Bossuyt ◽  
M. J. W. Koelemay ◽  
P. C. R. van der Vet ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Surgical Interventions

Neurodevelopmental Treatment (Bobath) for Children With Cerebral Palsy: A Systematic Review

2019 ◽  
Vol 34 (11) ◽  
pp. 679-686 ◽  
Author(s):  
Márcia Andréa Zanon ◽  
Rafael Leite Pacheco ◽  
Carolina de Oliveira Cruz Latorraca ◽  
Ana Luiza Cabrera Martimbianco ◽  
Daniela Vianna Pachito ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Cerebral Palsy ◽  
Physical Therapy ◽  
Randomized Clinical Trials ◽  
Risk Of Bias ◽  
The Body ◽  
Current Evidence ◽  
Children With Cerebral Palsy ◽  
Protocol Registration

Aim: To assess the effects of neurodevelopmental treatment for children with cerebral palsy. Methods: We conducted a systematic review following the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions and reported in accordance to PRISMA Statement. Through a comprehensive literature search we considered all randomized clinical trials that compared neurodevelopmental treatment with conventional physical therapy for children with cerebral palsy. We used the Cochrane Risk of Bias Table to assess the risk of bias of the included randomized clinical trial, and the GRADE approach to evaluate the certainty of the body of the evidence. Results: We found 3 randomized clinical trials (2 published and 1 ongoing) comprising 66 children. Published randomized clinical trials presented methodological and reporting limitations and only 1 provided data for outcomes of interest. No difference between neurodevelopmental treatment and conventional physical therapy was found for gross motor function (mean difference 1.40; 95% confidence interval –5.47 to 8.27, low certainty evidence). Conclusion: This review found that the effects of neurodevelopmental treatment for children with cerebral palsy are still uncertain. Further studies are required to assess the efficacy and safety of neurodevelopmental treatment for this purpose and until there, current evidence do not support its routinely use in practice. Number of protocol registration in PROSPERO database: CRD42017082817 (available from https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=82817 ).

Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials

2009 ◽  
Vol 23 (5) ◽  
pp. 394-407 ◽  
Author(s):  
Cidronio Albavera-Hernández ◽  
Jorge M Rodríguez ◽  
Alvaro J Idrovo
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Randomized Clinical Trials ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

2019 ◽  
pp. 1-9 ◽  
Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Inflammatory Mediators ◽  
Randomized Clinical Trials ◽  
Randomized Controlled Clinical Trials ◽  
Patients With Cancer ◽  
Reactive Protein ◽  
Randomized Controlled ◽  
Human Adults ◽  
Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

ANTERIOR VERSUS POSTERIOR MYOTOMY DURING POEM FOR THE TREATMENT OF ACHALASIA: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

2019 ◽  
Author(s):  
E Rodríguez de Santiago ◽  
N Mohammed ◽  
A Manolakis ◽  
Y Shimamura ◽  
M Onimaru ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document